Clinical trials: Disease, Hodgkin
Non-Hodgkin's Lymphoma, Multiple Myeloma
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
This is an open-label, single-arm, multicentre study conducted in Spain to estimate the effectiveness of palifermin administered at a dose of 60 mg/kg/day IV for 3 consecutive days before the start of the conditioning regimen and…
- Trial name
- NCT00352703
- Testing
- Kepivance (Palifermin)
- Volunteers
- 145 people
- Sponsor
- Swedish Orphan Biovitrum
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
This phase I trial tests the safety, side effects and best infusion dose of genetically engineered cells called anti-CD19/CD20/CD22 chimeric antigen receptor (CAR) T-cells following a short course of chemotherapy with…
- Conditions
- Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
- Trial name
- NCT05418088
- Testing
- Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sumithira Vasu
Hodgkin Disease Lymphoma
A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma
This is an open-label, multicenter, randomized, phase 3 trial to evaluate the efficacy of Penpulimab vs. standard chemotherapy selected by investigator in patients with relapsed or refractory classic Hodgkin's lymphoma.
- Trial name
- NCT05244642
- Testing
- Penpulimab, Investigator's choice of Chemotherapy
- Where
- 6 sites in China
- Volunteers
- 60 people
- Sponsor
- Akeso
Lymphoma, Non-Hodgkin
Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL
Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies.
- Trial name
- NCT04638270
- Testing
- anti-CD19 FasT CAR-T cells
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Xinqiao Hospital of Chongqing
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying how well rituximab works in preventing acute graft-versus-host disease (GVHD) in patients undergoing a donor stem cell transplant for hematologic cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT01044745
- Testing
- rituximab, mycophenolate mofetil, tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Nebraska
B-cell Non-Hodgkin's Lymphoma
A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL
This is a Phase 1, open-label, single-arm study to evaluate tolerability, safety and efficacy of RJMty19 in adult subjects with r/r B-NHL.
- Trial name
- NCT06314828
- Testing
- RJMty19 (CD19-CAR-DNT cells)
- Volunteers
- 30 people
- Sponsor
- Guangdong Ruishun Biotech Co., Ltd
Lymphoma
Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy may kill more cancer cells.
- Trial name
- NCT00398554
- Testing
- cyclophosphamide, doxorubicin hydrochloride, etoposide
- Where
- 12 sites in Germany, Switzerland
- Volunteers
- 16 people
- Sponsor
- Christine Mauz-Körholz
High-grade Lymphoma
Astragalus for Symptomatic Alleviation in High-grade Lymphoma
Lymphoma is a malignant disease of the lymph nodes. There are different types of lymphoma: when some of the lymphomas are indolent and require only follow-up, in cases of aggressive lymphoma or indolent lymphoma with a burden of…
- Trial name
- NCT06510530
- Testing
- Astragalus
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Bnai Zion Medical Center
Anaplastic Large Cell Lymphoma, ALK-Positive
A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma
The purpose of this study is to define the objective response rates (ORR) of Lorlatinib in subjects with ALK+ lymphomas resistant or refractory to ALK inhibitors.
- Trial name
- CRU3 (NCT03505554)
- Testing
- Lorlatinib
- Where
- 2 sites in Italy
- Volunteers
- 9 people
- Sponsor
- University of Milano Bicocca
Non-Hodgkin Lymphomas
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
This is a phase II open label study that looks at the efficacy and toxicity of Ofatumumab monotherapy in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT01078922
- Testing
- Ofatumumab
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Oncology Specialists, S.C.
Anxiety Depression (Mild or Not Persistent)
Clinical Trials to Evaluate Neurophysiological and Neuropsychological Effects of a Mindfulness-based Intervention
Depression and anxiety are conditions with a high prevalence in the world population and youth are no exception. In developing countries it is reported that given the conditions of social disadvantage, anxiety and depression are…
- Trial name
- PRESENTE-IA (NCT06618339)
- Testing
- Mindfulness-based intervention
- Where
- Mexico
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de Baja California
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
This study is a multi-center, open-label, single-arm, non-randomized phase II clinical study in order to evaluate the safety and efficacy of zanubrutinib, lenalidomide plus R-CHOP (ZR2-CHOP) as the first-line therapy for…
- Trial name
- ZR2-CHOP (NCT05200312)
- Testing
- Zanubrutinib, Lenalidomide, Rituximab
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Diffuse, Large B-Cell, Lymphoma
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
The purpose of this study is to comparing the Efficacy and Safety between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients.
- Trial name
- NCT02867566
- Testing
- IBI301 plus CHOP, Rituximab plus CHOP
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
This phase I trial studies the best dose and side effects of tazemetostat in treating patients with solid tumors or B-cell lymphomas with liver dysfunction that have spread to other places in the body or cannot be removed by…
- Conditions
- Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT03217253
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Tazemetostat
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma
Co-administration of CART22-65s and huCART19 for B-ALL
This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).
- Trial name
- NCT05674175
- Testing
- Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s), Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Stephan Grupp MD PhD
Leukemia, B-cell, Lymphoma, B-Cell
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.
- Trial name
- NCT04648475
- Testing
- CD19 and CD22 targeted CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Multiple Myeloma, Cutaneous Lymphoma
ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells
Hematopoietic stem and progenitor cells (HSPC) are used for transplantation in patients undergoing high dose therapy for the treatment of a range of cancers.
- Trial name
- NCT00400556
- Testing
- ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Classical Hodgkin Lymphoma
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHL.
- Trial name
- NCT03471351
- Testing
- Tenalisib, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Rhizen Pharmaceuticals SA
Hodgkin Disease, Lymphoma, Non-Hodgkin
Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases
Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases
- Trial name
- NCT00538551
- Testing
- Database
- Where
- Saudi Arabia
- Volunteers
- 350 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Diffuse Large B-cell Lymphoma
Erythropoietin for Management of Anemia Caused by Chemotherapy
This is a phase Ⅱ study of erythropoietin for management of anemia caused by chemotherapy in patients with Diffuse Large B-cell Lymphoma.
- Trial name
- NCT02890602
- Testing
- Darbepoetin alfa, R-CHOP
- Volunteers
- 53 people
- Sponsor
- Kosin University Gospel Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.